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ABSTRACT
Objectives: To compare the motives and experiences of
different ethnic groups participating in a randomised
double blind placebo-controlled trial of montelukast in
preschool wheeze, and to assess parents’ or guardians’
understanding of trial procedures and their implications,
including the collection of genetic material.
Design: Qualitative interviews with parents or guardians.
Setting: Interviews occurred in the homes of London
children recruited to a national multicentre clinical trial
following primary and secondary care attendance with
wheeze.
Participants: 42 parents (20 of Bangladeshi origin, 10
white UK, 12 other ethnicities) of preschool children
enrolled in a clinical trial.
Results: Bangladeshi families were relatively reluctant to
participate in the qualitative study, despite strong
engagement with the parent study. Anxiety related to
wheezing was a common primary motive for trial
enrolment. Parents viewed the trial as a route to
improved treatment. Verbal delivery of trial information
appeared more effective than study literature,
especially for Bangladeshi families, with low parental
literacy and high levels of trust in medical professionals
potential contributors to this effect. All ethnic groups
expressed a low understanding and/or retention of
essential study concepts such as randomisation and
genetic testing.
Conclusions: Bangladeshi families are particularly
motivated to participate in clinical trials despite variable
comprehension of study concepts. This motivation is
more strongly contingent on strong researcher-subject
rapport than on the quality of study literature. Trial teams
seeking to recruit from South Asian populations should
emphasise face-to-face verbal explanation of trial
concepts and procedures and consider modified trial
literature.
INTRODUCTION
Background
The under-representation of South Asians
and other ethnic minority groups in clinical
trials affects the generalisability of study ﬁnd-
ings and ultimately contributes to inequities
in access to healthcare.1 2 Marked ethnic dis-
parities exist in asthma outcomes3 and
ethnically delineated barriers to participation
in trials concerning asthma interventions
have been identiﬁed. These include a
residual stigma attached to the asthmatic
label, anxieties related to understanding the
implications of participation, worries about
the effects of trial medications, as well as cost
and time concerns.4 Suggested solutions
include provision of incentives, use of multi-
lingual trial literature, employment of per-
sonal approaches and addressing researchers’
reluctance to invite participation from the
full cultural and linguistic spectrum.4–6
Currently, there is poor understanding of the
perspective of ethnic minority parents involved
in paediatric clinical trials. Previous work has
ARTICLE SUMMARY
Article focus
▪ South Asians and ethnic minorities are under-
represented in clinical trials, affecting the applic-
ability of results.
▪ South Asian group representatives suggest that a
personal approach by researchers may improve
recruitment.
▪ Parents enrolling young children in trials often
have poor understanding of the implications of
consent, whether this varies across ethnic groups
is unknown.
Key messages
▪ Self-interest as well as altruism influence paren-
tal decision to enrol in a paediatric respiratory
clinical trial.
▪ Decision to enrol is influenced more by trust in
the research team than by written information.
▪ Careful verbal explanations of trial procedures,
advantages and disadvantages are particularly
important for parents of Bangladeshi origin.
Strengths and limitations of this study
▪ Data from a study population historically difficult
to engage in quantitative or qualitative clinical
research.
▪ The sample size is small, but adequate to
achieve data saturation.
▪ There is an absence of data on parents declining
to participate in the parent study.
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explored the role of parents as responsible decision makers
coreliant on the researchers and research governance pro-
cedures for guidance and protection.7 Signiﬁcant elements
include parents’ poor comprehension of the trial process,8
the parental emotional turmoil related to paediatric illness
and confusion born of the blurring of ethical boundaries
between clinical and research practice.9–11
Parent study
The current study is embedded within a randomised
controlled trial (the parent study) of the genetic deter-
minants of the efﬁcacy of intermittent montelukast in
preschool wheeze (PSW) and provides an opportunity to
investigate the perspectives of the parents of trial partici-
pants. It was hypothesised that a genetically determined
subgroup of patients (with higher urinary inﬂammatory
mediators) would respond better to montelukast (have
reduced unscheduled medical attendance) than their
peers.
Qualitative study
PSW is a common, but poorly understood, disease of
early childhood equally prevalent in UK children of
South Asian and European origin.12 The ethnically
diverse setting of the recruiting institution permits the
principal aim of this study which was to compare atti-
tudes and experiences of participating families across
ethnic groups, including a signiﬁcant number of partici-
pants of South Asian (Bangladeshi) origin. A secondary
aim arises from the fact that both positive and negative
public perceptions of pharmacogenetics exist.13 A recent
focus group study involving diverse ethnic minority parti-
cipants in biobank research found generally positive atti-
tudes, with participation driven by perceptions of
personal or collective beneﬁt, despite limited under-
standing of genetics.14 15 Hence, this work aims to
describe ethnic variation in participants’ understanding
of the genetic element of the trial.
METHODS
Parent study procedures
Preschool children with a history of wheezing were
recruited by a small team of children’s research nurses and
secondary care paediatricians following hospital attend-
ance for wheeze or after receiving information from their
primary care physician. For hospital attendees, recruitment
occurred immediately prior to or shortly after discharge
from hospital. Families received a trial information pack
and subsequently discussed the study with the research
team. Written and real-time verbal Bengali translation was
available as required. Amenable parents then gave written
informed consent (to paediatrician, research nurse or
both) after which a mouth swab (for leukotriene-pathway
genes) and urine sample (for leukotriene levels) were col-
lected. Parents agreed to administer a 10-day course of oral
medication (randomly allocated to montelukast or
placebo) at the onset of a cold or wheezing symptoms, and
to complete a daily diary record for the same period. They
also received progress calls from the clinical research team
at regular intervals and were encouraged to phone if they
had any queries or concerns. Children were followed up
for 1 year and the need for unscheduled respiratory
medical attendance assessed. The qualitative study (QS)
was based at the East London host centre of this multicen-
tre trial and involved an audio-recorded semistructured
interview with parents of enrolled children.
Participant recruitment
All participants in the trial and the qualitative substudy
received written information about the study at recruit-
ment. One hundred and thirty-nine parents gave formal
written consent for their child to be enrolled in the trial
and 85 of these parents gave written consent to a qualita-
tive interview at the same time (table 2). The initial plan
was to sample purposefully from the 85 consenting
parents, aiming for maximum variation16 in terms of
ethnicity, gender and other variables and then theoretic-
ally, according to iterative analysis of initial interviews.
Data generation
Individual interviews were considered the most appropri-
ate method for data collection as this ensured conﬁden-
tiality. A semistructured interview guide (box 1) for the
interviews was developed following a literature review
and discussions between VM and CS.4 7 17 18 Interviews
were conducted by VM, an experienced non-clinical
qualitative researcher with an interest in the develop-
ment of healthcare services in partnership with the
patient population. Each interview took place in the
parent’s home and lasted 25–60 min. Preschool children
were present in many instances. Interviews were con-
ducted in English except one interview which required
the assistance of a Bengali interpreter.
Data analysis
Interviews were audio-recorded and professionally tran-
scribed verbatim. CS also reviewed a sample of interview
transcripts during the course of the data collection period.
Table 1 Reasons given for decline or no response to
request for qualitative interview
Reasons given for decline or no
response to request for qualitative
interview
Number
of
parents
No response 14
Declined—no reason given 11
Declined—no time (employment related) 4
Declined—unable to speak English 5
Declined—no time (heavily pregnant or caring
for newborn)
4
Declined—annual or religious or imminent
extended holiday
5
Total number of parents 43
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Transcripts and ﬁeld notes were imported into NVivo9, a
qualitative data analysis programme.19 VM and CS devel-
oped a coding framework that drew on the research ques-
tions, previous research about patient experiences of
taking part in clinical trials and themes that emerged in
the course of the analysis. The data were systematically
coded and analysed using a modiﬁed grounded theory
approach20 incorporating the constant comparison tech-
nique to elicit key themes and explore deviant cases.21 22
Ethics
The study was reviewed and granted approval by the
South East Research Ethics Committee (09/H1102/
110). Written informed consent for QS was included as
part of the parent study consent process and recon-
ﬁrmed immediately before the qualitative interviews
took place. The QS adhered to the RATS qualitative
research review guidelines.23
RESULTS
Of the 85 parents who gave written consent to structured
interview at parent study enrolment, only half subse-
quently participated in a face-to-face interview. The
reasons for non-participation are as stated in table 1.
The remaining 42 parents agreed to a face-to-face
interview, which took place over a 7-month period.
There is no ideal sample size for qualitative studies24
and this was a sufﬁcient number of interviews within this
opportunist sample to achieve data saturation.
At QS commencement, 139 families had consented to
study enrolment; Bangladeshi participants were relatively
over-represented in the parent study and white British
under-represented. Bangladeshi parents taking part in
the parent study were less likely than parents of ‘other’
ethnicity to be interviewed for the study reported here.
Table 2 shows ethnically delineated differences in study
participation.
We proceed to outline the characteristics of partici-
pants and then report on the themes that emerged from
the interviews. These include
1. The reasons the parents gave for enrolling their child
in the trial.
2. Participating parents’ experience of the consent
process and understanding of written and verbal
information provided at the outset of the trial, in par-
ticular their understanding of the randomisation
process.
3. Participating parents’ understanding and response to
the collection of genetic information.
4. The nature of participating parents’ consultations
with other people before deciding to take part.
Throughout, we report on differences and similarities
between Bangladeshi and other participants.
Characteristics of participants
The majority of respondents were women. Bangladeshi
participants had poorer spoken English than other
groups and were less inclined to disclose their level of
schooling, perhaps indicating sensitivity regarding poor
educational attainment. Most households reported at
least one working parent, but the numbers engaged in
full time, part time or shift work were unclear due to
guarded responses.
Parents of children in all groups reported anxiety
related to their helplessness during wheezing attacks,
Table 2 Patterns of participation by ethnic group25
Bangladeshi White British Other* Total
Percentage of local <15 population
by ethnic group†
22200 (50%) 14500 (33%) 7500 (17%) 44200 (100%)
Parents with children enrolled in parent
study at time of QS
94 (68%) 24 (17%) 21 (15%) 139 (100%)
Parents consenting to QS at time of
enrolment to parent study (% of parents
enrolled, 95% CI)
48 (51%, 41–61) 17 (71%, 51–85) 20 (95%, 76–100) 85
Qualitative interview completed (% of
parents enrolled, 95% CI)
20 (21%, 14–31) 10 (42%, 24–61) 12 (57%, 37–76) 42
*Other interviewed parents: Africa (n=6), Caribbean (n=2), South America (n=1), Middle East (n=1), China (n=1).
†There is no information available regarding ethnicity of the local under-5 population. Data regarding under-15 children are deemed an
appropriate surrogate given that the overwhelming majority of local preschoolers survive to their teens and there is no evidence of an ethnically
divergent change in local birth rates in recent years.
QS, qualitative study.
Box 1 Topics included in the semistructured interview guide
1. Family and child background information
▸ Child’s history of wheeze
▸ Treatment and diagnosis
▸ Impact on child/parents/family
2. Parents experiences of joining the trial
▸ Motivations
▸ Consent and research governance processes
▸ Attitudes towards the collection of DNA and genetically
guided therapy
3. Parents attitudes to and experiences of giving the trial drug to
their child.
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often driven by the ﬁrst hospital presentation. Major
fears were of the potential for death or major long-term
disability. These concerns drove a preoccupation with
monitoring their child’s health, together with anxiety
about the potential progression of a cold to a wheeze
with the attendant hospital visit, investigations and treat-
ment. These fears were important drivers for trial partici-
pation, with hopes that participation might contribute to
improved treatment for wheeze. Box 2 shows interview
extracts relevant to this theme.
This was the emotional context within which parents
were approached by the clinical trial team and asked if
they would consider enrolling their child into the parent
study. Parents reported being approached while inpati-
ents or during follow-up appointments in primary or sec-
ondary care. Most children were already on prescribed
medication for wheeze.
Half of the parents (11/20 Bangladeshi, 6/10 UK, 4/12
other) said that their primary reason for enrolling their
child was that they hoped it would beneﬁt their child in
curtailing or curing the wheeze. A subset of these believed
that the trial medicine represented an individual treat-
ment regime for their child, perhaps conﬂating research
with personal treatment. Others also viewed it as a route to
additional information, treatments and medical attention
by skilled physicians (box 3).
A third (15/42, of which 5/20 Bangladeshi, 4/10 UK,
6/12 other) said that their aim was to help other chil-
dren by contributing to the advancement of medical
knowledge (although beneﬁt to others was secondary to
a consideration of potential beneﬁt to their own child).
Only four parents (2/10 UK, 2/12 other) voiced a
wholly altruistic outlook by pointing out that the results
of the trial would be unlikely to beneﬁt their own child.
A few parents (2/20 Bangladeshi, 1/10 UK, 0/12
other) based their decision to participate in the trial pri-
marily on their trust in the research team, these families
appeared not to differentiate between trial researcher
and healthcare provider roles. Parents felt reassured that
they could opt out of the trial at any time and, particu-
larly if their child experienced side effects.
Beliefs about the acceptability to their child and the
effects of the substance they were given—whether mon-
telukast or placebo—were clearly important motives in
maintaining or discouraging continuing participation
(box 4). Four of 20 Bangladeshi parents (but no others)
believed there would be no side effects, reporting that
this was what the trial researcher had told them. Even
parents with a well-informed understanding of the trial
process said they would consider withdrawing their child
if they believed the medication was not having a beneﬁ-
cial effect. Three (one from each ethnic group) had
already decided to discontinue because their child did
not like the medication or because it did not appear to
be effective, or because of perceived adverse effects.
Three more (2/10 UK, 1/12 other) said they would con-
sider dropping out for similar reasons if they believed
that their child had been allocated the placebo drug, or
Box 2 Anxieties about wheeze in children
When I am putting him in the shower he was difficult to breath,
he goes (makes gasping sound) with his hand in his mouth and I
was scared and then I had to call an ambulance…he stayed in
hospital for 2 days.(24F-Brazilian)
He wasn’t too good they said we have to keep him in and he
had oxygen up his nose. It was horrible. So he was in hospital
for 3 days. That was the worst 3 days of my life. (41F-UK)
I’m so worried. My God. I know asthma may kill so I’m very
worried (01F-Bangladeshi)
‘My worst fear was that if I’m not with him or something like
that….not breathe or…I don’t know, I don’t know much about
asthma. I don’t want him to get that. (08F-Egyptian)
‘I can remember saying to (husband) very clearly if he dies
don’t come and collect me because I don’t want to leave without
him’ (19F-Caribbean)
‘I really didn’t know how bad it was and how it can affect a
child. And I really didn’t know it was going to be the start of this
long process of hospital after hospital after hospital.’ (09F-UK)
‘I am looking for a final treatment for her because this disease
is not good for her health you know so I am looking for much
better treatment for her and to find a treatment which is better for
her whole life.’ (33FM-Bangladeshi).
Box 3 Other reasons for taking part
Benefit to child
I wanted to see if it helps my daughter, to see if it got rid of
her wheeze. (42F-Bangladeshi)
They said if you do this study your daughter is going to get
better. (25F-Bangladeshi)
It’s an extra medicine for my daughter that will help her, and
it helps her stay at home rather than going to the GP or hos-
pital all the time. (42F-Bangladeshi)
A very good way of you know, getting him seen by good
doctors … and hopefully getting answers you’re looking for’
(05F-UK)
Benefit to others
[My child] won’t really benefit but from it …this is obviously
a trial so that they can try and prescribe this medicine in the
future for children. (29F-UK)
It’s good for the future. All children. Not for her [child]
because she has already got it now, but yes, all children of
the world. (40F-African)
Hopefully it’s good for other children and good for her.
(6M-Chinese)
Trust in clinicians
I thought like, you know, it’s from hospital, obvious it’s
good for him. So the doctor knows better than us. (02F-
Bangladeshi)
Being in control
It’s reassuring that they kept saying that at any time we can
pull out. (21F-Bangladeshi)
They explained to me that the main side effect was sleep like
sleep disturbance erm... and obviously if it was too much
then just stop. (04F-UK)
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if the medication seemed ineffective or harmful, indicat-
ing that subject recruitment and retention is driven
strongly by the perceived likelihood of personal beneﬁt.
Information and consent
All parents reported satisfaction with the initial trial
information they had received and that all queries were
answered adequately. Retention was poor however, and
by the time of the interview few could recall signiﬁcant
detail. The decision to consent was strongly inﬂuenced
by the meeting with the clinical team.
The patient information leaﬂet (PIL) was translated
from English into Bengali, but not into other languages
as Bangladeshis are by far the largest local
non-English-speaking minority, with a disproportionately
reduced likelihood of English literacy in comparison to
other, rarer language groups (table 3). Interviewees were
often evasive regarding their reading of the PIL, suggesting
that this was an area of sensitivity for some respondents.
Just 7 (41%) of 17 Bangladeshi respondents who gave
direct answers claimed to have read the leaﬂet (compared
with 15/16 (93%) of non-Bangladeshis); a further seven
said that they had not and three said that other family
members had read it for them. Box 5 shows comments
made about the PIL. The length and detail of the PIL
appeared to discourage reading in some (mainly
Bangladeshi) respondents, placing the emphasis more
ﬁrmly on personal interaction with researchers for commu-
nication of trial information.
Understanding the research process
Just over one-third of parents understood the principle
of randomisation to some degree (5/20 Bangladeshi,
7/10 white UK, 3/12 others; see box 6). Bangladeshi
families were least aware that a DNA sample had been
taken from their child (6/20 Bangladeshi were aware,
9/10 UK, 9/12 others). Despite poor comprehension of
personalised medicine and genetic testing concepts,
most respondents viewed the genetic component of the
study positively.
Consulting others
There were some differences between ethnic groups in
how decisions were made to enrol their child in the
trial. Some decided to consent as soon as they were
approached but others sought advice from other
people. Some (4/20) Bangladeshi respondents reported
that they relied entirely on the medical profession to
guide them, but they were the only group to express
this. Some non-Bangladeshi respondents were able to
call on medically qualiﬁed family members for their
advice or made use of the internet and other sources of
pharmaceutical information. Very few respondents
(3/42), all of white UK ethnicity, reported receiving
Table 3 Characteristics of qualitative interview
participants
Bangladeshi
White
UK Other
Demographics
Male 6 2 2
Female 14 8 10
Age in years (mean (SD)) 35 (7.8) 34 (6.2) 36 (4.3)
Language
First language
Bengali/Sylheti 19
English 1 10 4
French 2
Arabic 2
Mandarin 1
Creole 1
Portuguese 2
Fluency in spoken English*
Excellent 5 10 4
Good 1 0 0
Fair 5 0 5
Poor 9 0 3
Socioeconomic
Educational attainment
Left before 16 years 1
GCSE or equivalent 8 6 3
A level or equivalent 1 0 3
Graduate degree 1 4 3
Postgraduate degree 1 2
Not answered 8 1
Occupation of highest earner in family
Higher managerial,
administrative and
professional
1 2 2
Intermediate 3 1 3
Routine and manual 8 2 3
Student 1
Not answered 8 5 3
Total 20 10 12
*Interviewer’s judgement.
Box 4 Effects and acceptability of medication
They just told me there’s not going to be there, there is no side
effects at all. (23M-Bangladeshi)
Yes medicine he doesn’t like. (22F- Bangladeshi)
I don’t want there to be any side effects. Yes everything has
got side effects but, it’s the sleeping part and the behaviour that
was another thing. I didn’t want that to change. (41F-UK)
I think our first step would be if I thought he wasn’t on the
medicine, getting the medicine prescribed somewhere else.
(05F-UK)
I mean the only reason I would come out of the trial was if I
thought there was any erm... negative side effects. And we’re now
on our second dose of medicine and he’s been totally fine.
(10F-UK)
I’d go back to the hospital...and tell them the medicine you
give to me maybe don’t do anything. (07F-African)
The wheezing is still there and it was not going away, so I just
said, I just stopped giving to him, I said I didn’t think it was
helping him at all. (32F-Caribbean)
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negative views about the trial from family or friends.
Box 7 shows relevant extracts.
DISCUSSION
Summary of the main findings
A major reason for parents agreeing to enrol their child
in the trial related to their previous experiences of wit-
nessing their child having severe wheeze attacks. This
caused anxiety in many parents, regardless of ethnicity,
motivating them to ﬁnd an effective treatment. However,
some parents found it difﬁcult to distinguish between
clinical treatment and research despite receiving infor-
mation about the trial processes, including randomisa-
tion and the use of a placebo.
A second reason for enrolment was the reassurance
parents received that they would retain control, regarding
not only whether to remain in the study but also whether
and when they gave their child the study medicine.
Third, most parents had conﬁdence in the research
team and preferred face-to-face meetings with the clinical
trial researchers to reliance on written PILs. They could
ask questions directly of the research team and found the
prescribed and formalised information sheets too long.
While none said that they had received too much informa-
tion about the trial, few had read beyond the ﬁrst few
pages. It appears that verbal delivery of trial information
was more important than study literature. Bangladeshi
families demonstrated poor familiarity with essential trial
concepts at interview (table 4); however, it is unclear
whether this reﬂects poor initial understanding or poor
information retention. All parents report being satisﬁed
with the information received at recruitment; however,
although similar numbers of white and Bangladeshi
parents claim to have read the PIL (table 4), the informa-
tion density of the PIL may have prevented complete
reading (box 5), or re-reading when details had faded
from memory. The disproportionate effect on Bangladeshi
families may relate to the large number of non-responders
to the query regarding educational attainment (table 3),
where non-response may indicate a low educational level.
Despite this poor information level, Bangladeshi parents
were overrepresented in the parent study, reﬂecting a
desire to participate that was likely inﬂuenced by
researcher rapport (box 3 and 5) and a Bengali-speaking
team member, a linguistic beneﬁt that was lost in the
Box 7 Other sources of information and reassurance
It’s from hospital obvious it’s good for him. He…the doctor
knows better than us. (02F-Bangladeshi)
I told him [my husband] and he said OK if you want to go you
can go. (25F-Bangladeshi)
I looked at the internet I think……where I work we’ve got an
old copy of the BNF so I looked at that. (18M-UK)
I was pretty certain I think.. but his dad was a bit more reluc-
tant because he’s sort of thought it was a trial medicine.... and
then when I explained that montelukast was already a drug... and
if he has asthma and it gets progressively worse, there’s a good
chance it will be prescribed anyway, so.., (10F-UK)
Box 5 Comments about the patient information leaflet
Lots of pages. Yeah, little bit I read…He explained me nicely that
time. I understand what he’s saying but I can’t tell you now.
I can’t remember all of it. 01F-Bangladeshi)
Some of the first page and second page we did and then we
were happy with this. We read we are so happy some of the para-
graphs are very nice but it carried on and on. (15M-Bangladeshi)
That time I was very busy and I don’t have time to read it, and
when I had time I forgot. (25F-Bangladeshi)
I understood what she explained so I didn’t really bother to
read that much. (38F-Bangladeshi)
Yes of course, I read everything. Erm, I did read it, I could
have read more, erm but I am one of the people who reads every-
thing. I am used to reading complicated stuff in my work anyway.
(30M-UK)
They were good explanatory, there was a lot of them but it’s
not the same as talking to somebody saying well look I’m worried
about and then they’ll they put me right. I had a better under-
standing and you can’t ask a question on a bit of paper. (09F-UK)
It told me everything I need to know to be able to start the
trial. (27F-Black UK)
Er....can’t remember. Something I have to think... because it
was a long time ago. (08F-Egyptian)
I read it, well both myself and my partner read it and we did
find it like yeah it was absolutely fine for us. (19F Caribbean)
I read it….Just first the introduction, the introduction this
research. (06M-Chinese)
Box 6 Understanding and acceptance of randomisation
and DNA component
Randomisation
I totally don’t know if the powder is the..er..blank one
(06M-Chinese)
Well they said they were going to test so many people with
this and so many people with that and then get the results and
see what. 17F-Bangladeshi)
We are in a trial and we could be given a placebo or cure
and that’s done on a group of kids. (26M-Middle Eastern)
Yes, so I could have a treatment that is sherbet in other
words. (27F-Black UK)
DNA component
They did tell me [its purpose] at the time but I really can’t
remember. (21F- Bangladeshi)
They told me, eh, I can’t remember, sorry. (39F-African)
It’s only if it didn’t hurt him, it was only a swab from his
mouth so no, that was fine. (04F-UK)
As long as it’s not invasive (08F-Eygyptian)
I’m sure it’s only used for the medical and not generally.
I think the only time it would be concerning is like I said if they
were going to share the information. (21F-Bangladeshi)
I haven’t really thought about it. It’s just part of the one part
of the study that needs to be that they’re looking at. I don’t think
there’s anything sinister being done. Everyone’s going to end up
on a DNA database somewhere. (05F-UK)
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translated PIL due to low literacy. Hence, parents gave
informed consent, but lacked a useful written record of the
details to which they had agreed.
The study found a lack of curiosity about research pro-
cesses and practices among all ethnic groups. Parents
were generally unconcerned regarding DNA collection,
with little awareness of controversies regarding the pro-
cessing of genetic material expressed by any ethnic
group. Parents’ primary concern in the parent study
regarded potential montelukast side effects.
The ﬁndings suggest an absence of interethnic discrep-
ancies in motivating factors for research participation. All
groups were united in their anxieties regarding PSW and
the need to ﬁnd an effective treatment. Bangladeshi
parents were distinguished by a greater respect for
medical opinion and a limited grasp of spoken and
written English which combined to increase their partici-
pation, but at the cost of limited understanding.
Strengths and limitations of the study
The study does not include parents who were unwilling to
take part in the trial or take part in the qualitative inter-
views. While recruitment of Bangladeshi participants to the
parent study was good, perhaps because one of the
research workers was ﬂuent in Bengali, it is clear (see table
2) that participation of these parents in the qualitative
interview study was less common. This reluctance was
perhaps related to concerns about coping with an inter-
view conducted in English or with the aid of an inter-
preter. Future qualitative studies of this sort may be able to
overcome this reluctance by employing a research worker
ﬂuent in the ﬁrst language of potential respondents.
Comparison with the existing literature
This study reinforces the existing qualitative literature26 27
on recruitment to trials for children in general, and in
the consent process in particular28; however, the novel
aspect of this study is the contrast between different
ethnic groups, especially in relation to understanding
and accessible information. The difﬁculty some parents
had in distinguishing clinical treatment from research
reﬂects previous reports,8–11 while the ﬁnding about par-
ental reassurance and sense of control are in line with
earlier work relating to consent by proxy.7–11 Studies on
lay understanding of the purpose of genetic sampling
have also found a lack of concern about this.14 15
Implications for the conduct of research
We concur with the view that representative ethnic minor-
ity participation in trials is feasible if researchers take
appropriate steps to facilitate this.5 It is clear that one of
the stumbling blocks can be the provision of information
in a ‘user unfriendly’ format. Modern ethics committees
demand highly detailed PILs which may perversely reduce
the quality of the consent decision by discouraging thor-
ough reading and reducing assimilation of information.29
This observation is supported by the current ﬁndings. As a
matter for debate, we suggest the introduction of a supple-
mentary and abbreviated PIL with a checklist of funda-
mental concepts to be covered during the informed
consent process (this would include the division between
researcher and clinician roles). This document should be
signed and a copy kept by both researcher and the study
participant. The counter argument is that an abbreviated
PIL would not fully inform parents; however, such a docu-
ment (used alongside a detailed consent discussion)
would add structure to and emphasise the importance of
the discussion and also serve as a palatable aide-memoire
for participants. The full PIL could be retained as a
detailed reference document for parents. Approaches
such as this may improve the quality and success of the
consent process across the ethno-social spectrum and their
investigation should be an avenue for future study.
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